TFS
RXRX icon

Thoroughbred Financial Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Thoroughbred Financial Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$67K – 716
2024
Q4 		$67K Sell
10,000
-5,000
-33% -$33.6K ﹤0.01% 679
2024
Q3 		$98K Buy
+15,000
New +$108K 0.01% 643

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Thoroughbred Financial Services's RXRX Position: Q1 2025 in Review

Thoroughbred Financial Services sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 10,000 shares — an estimated $67K sold.

Thoroughbred Financial Services first reported a position in RXRX in Q3 2024 and held it in 2 quarters. The position peaked at $98K in Q3 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Thoroughbred Financial Services reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Thoroughbred Financial Services sold 10,000 Recursion Pharmaceuticals shares in Q1 2025, an estimated $67K.
  • Thoroughbred Financial Services first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Thoroughbred Financial Services's Recursion Pharmaceuticals position peaked at $98K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Thoroughbred Financial Services's 13F filing for Q1 2025, filed 9 May 2025.